Entropy Neurodynamics achieves clinical milestone with repeatable psychedelic effects in TRP-8803 trial for binge eating disorder treatment.

Entropy Neurodynamics achieves clinical milestone with repeatable psychedelic effects in TRP-8803 trial for binge eating disorder treatment. All three patients dosed to date have demonstrated controlled psychedelic responses, with clinicians successfully replicating the onset, depth, and duration of effects. This reproducibility suggests strong therapeutic potential. The company's financial position strengthened significantly with a A$1.7 million R&D tax incentive refund, boosting cash reserves to A$6.4 million. Cohort 2 enrollment is advancing with four patients already enrolled in the twelve-patient trial. A newly granted Australian patent provides method-level intellectual property protection through 2042, covering the precision IV dosing regimen.